Mikael Sunnåker

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Heart Rate Variability

Tyrosine Kinase

Placebo Controlled

Top Venues

Clinical pharmacology and therapeutics

Pharmacology research & perspectives

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Chandrali S Bhattacharya, Patricia Ely Pizzato, Maria Heijer, Mikael Sunnåker, Julie Holden, Monika Trebski, Karin Nelander, Hodan Ali, Diyan K Genov, Malin Aurell, Anna Collén, Hans Ericsson
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat. British journal of clinical pharmacology (2024)
Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology research & perspectives 12 (2) (2024)
Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology research & perspectives 12 (2) (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics 116 (3) (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics (2024)